{"id":"W3001829806","doi":"10.1016/j.bbrc.2020.01.015","title":"The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension","year":2020,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University; University of Toronto; Robarts Clinical Trials; St. Michael's Hospital","funders":"Novo Nordisk Canada; Canadian Institutes of Health Research; Daiichi Sankyo Company; Amgen Canada; School of Medicine; Cleveland Clinic; Forest Laboratories; Ferring Pharmaceuticals; Bristol-Myers Squibb Canada; Duke Clinical Research Institute; Eisai; Ukrainian Research Institute, Harvard University; Boston Scientific Corporation; Boehringer Ingelheim; Eli Lilly and Company; Chiesi Farmaceutici; Abbott Laboratories; CSL Behring; Precast/Prestressed Concrete Institute; AstraZeneca Canada; Accident Compensation Corporation; Mayo Clinic; Bayer; Center for Social Inclusion; Medtronic; St. Jude Medical","keywords":"Empagliflozin; Medicine; Canagliflozin; Cardiology; Internal medicine; Pulmonary hypertension; Blood pressure; Heart failure; Diabetes mellitus; Type 2 diabetes; Endocrinology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003434978,0.0003262584,0.0007935037,0.0002648096,0.0001577257,0.0003360047,0.0002371059,0.0003282567,0.00103304],"category_scores_gemma":[0.0003308166,0.0001512741,0.0003703981,0.0001721827,0.0002822455,0.0004498126,0.0002297657,0.001758084,0.0002024135],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002694617,"about_ca_system_score_gemma":0.0003946068,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005886912,"about_ca_topic_score_gemma":0.0009891137,"domain_scores_codex":[0.9998925,0.00002194709,0.000007822356,0.00001201487,0.00003116334,0.0000346062],"domain_scores_gemma":[0.9998289,0.00001864202,0.00004656016,0.00001474373,0.00001457357,0.00007645284],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.1377738,0.01239514,0.01064339,0.001036731,0.0005475077,0.0003061391,0.0000911616,0.001856107,0.4973559,0.0007284938,0.007308807,0.3299568],"study_design_scores_gemma":[0.03427616,0.1124832,0.3226357,0.0002269195,0.001764161,0.001057259,0.0002952359,0.01601993,0.4881301,0.002039113,0.02093642,0.0001359152],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910241,0.005163203,0.001551635,0.0005929693,0.0002164469,0.00002894584,0.000275831,0.000215367,0.0009314165],"genre_scores_gemma":[0.992141,0.00381653,0.001374974,0.0003181525,0.0001773792,0.00006114105,0.0005430558,0.00002284931,0.001544889],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00103304,"threshold_uncertainty_score":0.003455877,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1846633630008089,"score_gpt":0.4365543621119126,"score_spread":0.2518909991111037,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}